Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Author:
Affiliation:
1. Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK
Funder
Institute of Cancer Research
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2016397
Reference95 articles.
1. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
3. Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
4. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
5. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non–Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison;Clinical Lung Cancer;2023-12
2. Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion;Advances in Therapy;2023-10-06
3. Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges;Genes;2023-10-04
4. Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need;International Journal of Molecular Sciences;2023-05-17
5. Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities;Journal of Medicinal Chemistry;2023-02-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3